{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-030813","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2025-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.771305+00:00","generated_at":"2026-05-17T04:03:25.429309+00:00","sec_items":["5.02","5.08","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Nuo Therapeutics raises CEO and COO salaries, sets Dec 16 annual meeting","bullets":["CEO David E. Jorden salary increased to $325,000 effective Oct 1, 2025.","COO Peter A. Clausen salary increased to $290,000 effective same date.","Annual meeting scheduled for Dec 16, 2025 at Houston principal executive office.","Shareholder proposals and director nominations deadline is Oct 20, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-030813","json":"https://secwatch.observer/filing/0001437749-25-030813.json","markdown":"https://secwatch.observer/filing/0001437749-25-030813.md","text":"https://secwatch.observer/filing/0001437749-25-030813.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925030813/0001437749-25-030813-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925030813/aurx20251009_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:03:25.429309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}